What is HC Wainwright’s Forecast for ACXP FY2025 Earnings?

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) – Research analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Acurx Pharmaceuticals in a research report issued on Wednesday, November 12th. HC Wainwright analyst M. Keller now expects that the company will earn ($5.72) per share for the year, up from their previous forecast of ($7.14). HC Wainwright has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($4.66) EPS and FY2027 earnings at ($4.15) EPS.

A number of other equities research analysts also recently weighed in on ACXP. Wall Street Zen downgraded Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, October 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Acurx Pharmaceuticals has an average rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Down 3.2%

Shares of NASDAQ:ACXP opened at $4.59 on Friday. The firm has a 50 day moving average of $5.28 and a 200 day moving average of $6.79. The company has a market capitalization of $9.59 million, a price-to-earnings ratio of -0.54 and a beta of -1.27. Acurx Pharmaceuticals has a 52 week low of $3.80 and a 52 week high of $35.80.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.23) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.38.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently bought a new stake in Acurx Pharmaceuticals stock. O Brien Greene & Co. Inc bought a new position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 60,000 shares of the company’s stock, valued at approximately $31,000. O Brien Greene & Co. Inc owned about 0.20% of Acurx Pharmaceuticals at the end of the most recent reporting period. 11.53% of the stock is currently owned by institutional investors and hedge funds.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.